Colossal Biosciences says de-extinction work could help human health and conservation
Overview
Colossal Biosciences CEO Ben Lamm says the company's dire wolf and woolly mammoth projects could produce conservation and human health benefits, including tools for DNA synthesis and gene therapies.
Lamm says Colossal is also pursuing the dodo, Tasmanian tiger and moa, and that it aims for a woolly mammoth birth in the 2030s.
The company was valued at $10.2 billion after a $200 million Series C round in July, according to the same report.
Written by AI from the articles below · updated Oct 10, 10:15 AM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- CNBC · TechnologyNewsColossal Biosciences says de-extinction work could help human health and conservation
AIColossal Biosciences CEO Ben Lamm says the company's dire wolf and woolly mammoth projects could yield conservation and human health benefits, including tools for DNA synthesis and gene therapies. Lamm says Colossal is pursuing work on the dodo, Tasmanian tiger and moa, and that it aims for a woolly mammoth birth in the 2030s. The company was valued at $10.2 billion after a $200 million Series C round in July.
Heat trend
Not enough continuous observations to show a trend yet.